Parathyroid Hormone

Most Common Uses:

1. Calcium Regulation and Bone Health: PTH plays a key role in regulating serum calcium levels by increasing calcium reabsorption in the kidneys, enhancing calcium absorption in the intestines, and promoting the release of calcium from bones. This process helps to maintain stable calcium levels essential for bone health, muscle contraction, nerve signaling, and cellular functions.
2. Treatment of Osteoporosis: Synthetic forms of PTH, such as Teriparatide (PTH 1-34), are used in the treatment of osteoporosis. By stimulating bone formation, PTH can help increase bone mineral density (BMD) and reduce the risk of fractures in individuals with osteoporosis, particularly postmenopausal women and men at high risk of fracture.
3. Management of Hypocalcemia: PTH is used to treat hypocalcemia (low blood calcium levels), which can result from parathyroid disorders or surgical removal of the parathyroid glands. By enhancing calcium reabsorption, PTH helps restore normal calcium levels in the blood.
4. Research in Bone Metabolism: PTH is widely studied in the context of bone metabolism, particularly in understanding the balance between bone resorption and formation. Researchers are exploring the potential of PTH in regenerative medicine and bone healing, including fracture repair.
5. Parathyroid Disorders: PTH is involved in diagnosing and managing conditions such as primary hyperparathyroidism and hypoparathyroidism. In hyperparathyroidism, excessive PTH secretion leads to elevated calcium levels, while in hypoparathyroidism, PTH deficiency results in low calcium levels, necessitating supplementation with PTH analogs or calcium.

Warnings and Cautions:

• Risk of Osteosarcoma: In animal studies, long-term use of Teriparatide (PTH 1-34) has been associated with an increased risk of osteosarcoma (bone cancer). For this reason, its use is typically limited to two years for osteoporosis treatment.
• Hypercalcemia Risk: Excessive PTH can lead to hypercalcemia (high calcium levels), which may result in symptoms such as nausea, vomiting, muscle weakness, and kidney stones. Monitoring of calcium levels is crucial during treatment.
• Contraindications: PTH should not be used in individuals with hyperparathyroidism, bone metastases, or Paget’s disease. It is also contraindicated in individuals with a history of radiation therapy to bones.

Dosages:

1. Osteoporosis Treatment: Teriparatide (PTH 1-34): For osteoporosis, the recommended dose is 20 mcg once daily via subcutaneous injection, typically administered in the thigh or abdomen. Due to the potential risk of osteosarcoma, treatment is generally limited to a maximum of 2 years. After discontinuation, patients are often transitioned to other osteoporosis treatments, such as bisphosphonates.
2. Hypocalcemia: PTH analogs or calcium supplements are used to manage hypocalcemia in individuals with hypoparathyroidism. Dosing varies based on the severity of the condition and the individual’s calcium levels. Synthetic forms such as Natpara (PTH 1-84) may be used at doses of 50 mcg to 100 mcg once daily.
3. Research and Experimental Use: In research settings, PTH dosing protocols can vary depending on the focus of the study, particularly in bone healing or regenerative medicine research. Subcutaneous injections of PTH (1-34) are often administered daily, with doses ranging from 5 mcg to 50 mcg per injection in experimental models.

Mechanism of Action: 

PTH binds to the parathyroid hormone receptor 1 (PTHR1) on target cells, primarily in the bones and kidneys. In bones, PTH stimulates osteoblasts (bone-forming cells) and indirectly activates osteoclasts (bone-resorbing cells), leading to increased calcium release from the bone matrix. In the kidneys, PTH enhances the reabsorption of calcium and reduces phosphate reabsorption. Additionally, it promotes the conversion of 25-hydroxyvitamin D to its active form, calcitriol, in the kidneys, which increases calcium absorption from the intestines.

In the context of bone health, intermittent administration of PTH (as in the case of Teriparatide) has anabolic effects, stimulating new bone formation and increasing bone mineral density. Continuous exposure to elevated PTH, however, can lead to bone resorption, emphasizing the importance of controlled dosing in therapeutic applications.

Benefits:

1. Enhanced Bone Density: PTH’s ability to stimulate bone formation and increase bone mineral density makes it highly effective in treating osteoporosis and reducing the risk of fractures.
2. Regulation of Calcium Homeostasis: PTH’s primary role in maintaining calcium balance is critical for overall bone and muscle health, as well as normal cellular functions. It is essential in managing conditions like hypocalcemia and parathyroid disorders.
3. Potential in Bone Healing: Research suggests that PTH may accelerate bone healing and improve outcomes in fracture repair, making it a potential therapeutic tool in orthopedic and regenerative medicine.
4. Treatment of Hypoparathyroidism: Synthetic PTH analogs provide an effective treatment option for individuals with hypoparathyroidism, helping to restore normal calcium levels and reduce symptoms associated with hypocalcemia.

Closing:

Parathyroid hormone plays a vital role in regulating calcium homeostasis and bone metabolism, making it an essential hormone in the body’s physiological processes. Synthetic forms like Teriparatide (PTH 1-34) are widely used in the treatment of osteoporosis, while PTH analogs are valuable in managing hypocalcemia and hypoparathyroidism. PTH’s ability to regulate bone resorption and formation offers significant therapeutic benefits, though long-term use requires careful monitoring due to potential risks like osteosarcoma. As research continues, PTH’s applications may expand, particularly in the fields of bone healing and regenerative medicine.